NASDAQ:MGNX - MacroGenics, Inc.
$16.21
 $-0.14
-0.86%
4:00PM EDT
2019-04-18
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  MGNX     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 61   199. 07   233. 87  
42 stocks rank:  3. 74 K 1. 43 K 1. 06 K
# analyst opinions:  10. 00   14. 48   14. 09  
mean recommendation:  1. 90   2. 09   2. 01  

quick ratio:  4. 38   5. 29   1. 92  
current ratio:  4. 49   5. 64   2. 40  

target price low:  15. 92   84. 50   115. 74  
target price avg:  23. 00   110. 73   137. 39  
target price high:  35. 10   136. 41   157. 80  
1-yr high:  25. 60   114. 11   138. 85  
last close:  16. 21   87. 56   116. 78  
50-day avg:  19. 66   95. 43   123. 53  
200-day avg:  18. 43   94. 13   121. 20  
1-yr low:  11. 11   72. 67   98. 41  
volume:  605. 26 K 2. 43 M 4. 85 M
50-day avg volume:  1. 15 M 2. 72 M 4. 97 M
200-day avg volume:  667. 90 K 2. 90 M 4. 58 M

1-day return:  -0. 86 % -0. 40 % 0. 07 %
this week return:  -6. 89 % -5. 72 % -4. 11 %
12-wk return:  38. 55 % 1. 78 % -0. 04 %
52-wk return:  -26. 65 % 10. 81 % 14. 09 %

enterprise value (EV):  632. 99 M 51. 19 B 117. 96 B
market cap:  791. 07 M 43. 00 B 104. 52 B
EBITDA:  -162. 93 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -3. 88   4. 34   13. 27  
enterprise/revenue (EV/R):  10. 53   68. 16   13. 68  
total revenue:  60. 12 M 10. 61 B 38. 24 B
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -171. 45 M 2. 20 B 4. 21 B

shares outstanding:  48. 80 M 570. 91 M 1. 24 B
shares:  47. 23 M 571. 02 M 1. 23 B
shares short:  5. 08 M 9. 93 M 16. 79 M
shares short prior month:  2. 41 M 9. 96 M 16. 58 M
short ratio:  3. 72   5. 31   3. 30  
short % of float:  16. 06 % 5. 81 % 2. 61 %
total cash/share:  4. 77   11. 13   9. 30  
total cash:  232. 86 M 6. 70 B 7. 10 B
free cash flow:  -116. 06 M 3. 58 B 4. 74 B
operating cash flow:  -153. 23 M 4. 14 B 6. 32 B

book value:  5. 74   12. 76   26. 84  
price/book:  2. 83   3. 08   -1. 74  
gross profits:  -130. 71 M 8. 03 B 34. 77 B
operating margins:  -284. 77 % -721. 97 % -88. 82 %
EBITDA margins:  -271. 00 % 10. 94 % 22. 54 %
profit margins:  -285. 18 % 7. 81 % 10. 60 %
gross margins:  -217. 40 % 37. 02 % 55. 68 %

1-yr max volatility:  130. 42 % --- ---
1-yr mean volatility:  0. 08 % 0. 03 % 0. 04 %

1-yr EPS:  -4. 19   2. 39   4. 08  
forward EPS:  -3. 87   3. 97   7. 14  
P/E:  -3. 87   13. 59   22. 83  
forward P/E:  -4. 50   -20. 05   14. 49  
PE/G:  0. 04   -1. 46   1. 68  
growth:  -89. 60 % 126. 81 % 29. 29 %
earnings high:  -0. 37   1. 02   1. 63  
earnings avg:  -0. 90   0. 76   1. 51  
earnings low:  -1. 27   0. 47   1. 39  
revenue high:  41. 37 M 2. 68 B 10. 71 B
revenue avg:  16. 59 M 2. 59 B 10. 49 B
revenue low:  2. 00 M 2. 49 B 10. 25 B
return on assets:  -30. 31 % -2. 80 % 5. 29 %
return on equity:  -63. 25 % -18. 52 % 7. 38 %
revenue growth:  -89. 60 % 92. 55 % 19. 15 %
revenue/share:  1. 47   13. 27   55. 24  

beta (1yr vs S&P500):  1. 28   1. 24   0. 93  
sharpe (1yr):  0. 15   0. 29   0. 60  

held % insiders:  7. 12 % 6. 38 % 3. 38 %
held % institutions:  78. 27 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : MGNX
.        + 0 =             0 :: INITIAL WEIGHT
.   + 57.946 =        57.946 :: inverse volume-to-price addition
.    + 47.12 =       105.066 :: spline projection addition
.     x 0.88 =        92.498 :: 13 weeks' performance factor
.    x 0.788 =        72.894 :: one-year gains+dividend factor
.    x 1.432 =       104.386 :: industry recommendation factor
.    x 2.408 =       251.359 :: symbol recommendation factor
.    x 1.154 =       290.185 :: EV/R factor
.    x 0.997 =       289.305 :: return on assets factor
.    x 0.994 =       287.475 :: return on equity factor
.    x 0.991 =         284.9 :: revenue growth factor
.    x 2.796 =       796.669 :: current ratio factor
.    x 1.138 =       906.955 :: quick ratio factor
.    x 1.126 =      1021.611 :: short ratio factor
.    x 2.028 =      2072.097 :: price-to-book factor
.    x 1.066 =      2209.758 :: 50-day avg > 200-day avg
.    x 2.109 =      4659.886 :: P/E weight
.    x 2.194 =     10221.958 :: PE/G factor
.    x 1.481 =     15141.628 :: beta factor
.    x 0.149 =      2260.719 :: sharpe factor
.    x 0.987 =      2230.247 :: target low factor
.    x 1.216 =      2711.391 :: target mean factor
.    x 1.108 =      3004.087 :: target high factor
.    x 1.312 =      3940.306 :: industry 2-weeks return factor
.     x 0.94 =      3705.692 :: "drift" penalty 3 days ago
.    x 0.944 =       3497.94 :: "drift" penalty 4 days ago
.    x 0.926 =      3238.923 :: overall "drift" factor
.    x 0.999 =      3236.462 :: largest single-day jump factor
.      x 1.0 =      3235.941 :: factor hist industry gain for week 15
.   cubeRoot =        14.791 :: reduced to standardize
.   - 22.422 =          0.61 :: add/subtract for performance
.                       0.61 :: FINAL WEIGHT for NASDAQ:MGNX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org